title: Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes.
abstract: The main purpose of the current study was to investigate the effect of a combination of alogliptin [a dipeptydil peptidase (DPP)-4 inhibitor] and lansoprazole [a proton pump inhibitor (PPI)] compared with alogliptin mono-therapy on glycemic control in patients with type 2 diabetes. This study was a multicenter randomized open-label study. One hundred type 2 diabetic patients were randomly assigned to either the alogliptin with lansoprazole group or the alogliptin mono-therapy group. After 3 months of treatment, the changes in hemoglobin (Hb)A1c, fasting plasma glucose (FPG), serum gastrin, homeostasis model assessment (HOMA)-β, and HOMA-insulin resistance (IR) were evaluated. A significant decrease in HbA1c and FPG, and a significant increase in HOMA-β were observed in both groups (all with P <0.0001). However, there were no significant differences in changes in HbA1c, FPG, or HOMA-β before and after therapy between the combination and alogliptin mono-therapy group (P =0.2945, P =0.1901, P =0.3042, respectively). There was a significant elevation of serum gastrin in the combination group compared with the alogliptin mono-therapy group (P =0.0004). This study showed that, although combination therapy with alogliptin and lansoprazole more effectively elevated serum gastrin levels compared with alogliptin mono-therapy, the effect of the combination therapy on glycemic control was equal to that of alogliptin mono-therapy during a 3-month study period.
authors.affiliation: Department of Internal Medicine, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan.
authors.forename: Kohzo
authors.initials: K
authors.lastname: Takebayashi
authors.forename: Shintaro
authors.initials: S
authors.lastname: Sakurai
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Suzuki
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Hori
authors.forename: Tomoko
authors.initials: T
authors.lastname: Terasawa
authors.forename: Rika
authors.initials: R
authors.lastname: Naruse
authors.forename: Kenji
authors.initials: K
authors.lastname: Hara
authors.forename: Mariko
authors.initials: M
authors.lastname: Suetsugu
authors.forename: Takafumi
authors.initials: T
authors.lastname: Tsuchiya
authors.forename: Hiromi
authors.initials: H
authors.lastname: Aoki
authors.forename: Takashi
authors.initials: T
authors.lastname: Hamasaki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shuutou
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Inukai
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007333:Insulin Resistance; D064747:Lansoprazole / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D010880:Piperidines; D064747:Lansoprazole; D014498:Uracil; C520853:alogliptin